Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting - 1 Jun 2026

Grochot Rafael, Bartolini Michela, Algaze Sandra, Reimann Patrick, Winder Thomas, Lenz Heinz-Josef, Fontana Elisa

Abstract excerpt

Alterations in the mitogen-activated protein kinase (MAPK) pathway play a central role in colorectal cancer (CRC) tumor biology, therapeutic response, and resistance. RAS oncogenic mutations are present in up to 35% of CRC; they represent constitutively active molecular switches that impair GTP hydrolysis and promote ligand-independent signaling. The development of allele-specific KRAS G12C inhibitors exploits a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to KRAS gene

Share to Molecular Targeted Therapy

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Signal Transduction

Share to Translational Research, Biomedical

Source

Identifiers

PMID: 42030498
DOI: 10.1200/EDBK-26-516576

Genes

BRAF
EGFR
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 12 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics.PMID 42030498Read ↗

EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance.Semantic proximity Read ↗

KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine.Semantic proximity Read ↗

An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development.Semantic proximity Read ↗

Update on Emerging Therapies for Advanced Colorectal Cancer.Semantic proximity Read ↗

KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.Semantic proximity Read ↗

Strategies to tackle RAS-mutated metastatic colorectal cancer.Semantic proximity Read ↗

Targeting the KRAS Oncogene for Patients with Metastatic Colorectal CancerSemantic proximity Read ↗

RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update.Semantic proximity Read ↗

Targeting BRAF and RAS in Colorectal CancerSemantic proximity Read ↗

Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.Semantic proximity Read ↗

Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.